Literature DB >> 9017043

The ability of bacteria to use Na-hyaluronate as a nutrient.

C Costagliola1, A Del Prete, N R Winkler, P Carpineto, M Ciancaglini, R Piccolomini, L Mastropasqua.   

Abstract

The objective of this study was to test bacteria ability to use Na-hyaluronate as a nutrient in vitro. Thirteen bacteria strains were tested in three different media: specific culture medium, agar-Healon medium and agar-Healon GV medium. The bacterial growth criteria were determined by counting the number of new colonies appearing at each observation time (0, 24, 48 and 72 h). The results were expressed as the percentage of growth in agar-Na-hyaluronate compared to each corresponding specific culture medium. After 24 h in the medium containing agar-Healon, S. aureus, S. epidermidis, S. pyogenes and S. viridans grew using hyaluronic acid as a nutrient. The percentage of growth of these species remained constant over the follow-up period. The other bacteria strains tested were unable to use Healon as a nutrient. After 24 h of incubation in the medium containing agar-Healon GV, S. aureus, S. epidermidis, S. pyogenes, and S. viridans exhibited about 20% growth. Subsequently, this percentage slowly increased to about 50%. The other bacteria stains tested were unable to employ Healon GV as a nutrient. With the exception of Staphylococci and Streptococci, the other species do not synthesize the necessary enzymes to break glucosidic bonds, therefore neither concentration of hyaluronic acid can be utilized as a source of carbohydrate for their survival in culture media.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9017043     DOI: 10.1111/j.1600-0420.1996.tb00736.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  8 in total

1.  Streptococcus pneumoniae can utilize multiple sources of hyaluronic acid for growth.

Authors:  Carolyn Marion; Jason M Stewart; Mia F Tazi; Amanda M Burnaugh; Caroline M Linke; Shireen A Woodiga; Samantha J King
Journal:  Infect Immun       Date:  2012-02-06       Impact factor: 3.441

2.  Staphylococcus aureus hyaluronidase is a CodY-regulated virulence factor.

Authors:  Carolyn B Ibberson; Crystal L Jones; Shweta Singh; Matthew C Wise; Mark E Hart; Daniel V Zurawski; Alexander R Horswill
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

Review 3.  Resilience in the Face of Uncertainty: Sigma Factor B Fine-Tunes Gene Expression To Support Homeostasis in Gram-Positive Bacteria.

Authors:  Claudia Guldimann; Kathryn J Boor; Martin Wiedmann; Veronica Guariglia-Oropeza
Journal:  Appl Environ Microbiol       Date:  2016-07-15       Impact factor: 4.792

4.  Two novel functions of hyaluronidase from Streptococcus agalactiae are enhanced intracellular survival and inhibition of proinflammatory cytokine expression.

Authors:  Zhaofei Wang; Changming Guo; Yannan Xu; Guangjin Liu; Chengping Lu; Yongjie Liu
Journal:  Infect Immun       Date:  2014-04-07       Impact factor: 3.441

5.  Influence of hyaluronic acid on bacterial and fungal species, including clinically relevant opportunistic pathogens.

Authors:  Andrea Ardizzoni; Rachele G Neglia; Maria C Baschieri; Claudio Cermelli; Manuela Caratozzolo; Elena Righi; Beniamino Palmieri; Elisabetta Blasi
Journal:  J Mater Sci Mater Med       Date:  2011-09-04       Impact factor: 3.896

6.  In-Vitro Antibacterial Activity of Curcumin-Loaded Nanofibers Based on Hyaluronic Acid against Multidrug-Resistant ESKAPE Pathogens.

Authors:  Petr Snetkov; Elizaveta Rogacheva; Arina Kremleva; Svetlana Morozkina; Mayya Uspenskaya; Liudmila Kraeva
Journal:  Pharmaceutics       Date:  2022-05-31       Impact factor: 6.525

7.  Hyaluronan Modulation Impacts Staphylococcus aureus Biofilm Infection.

Authors:  Carolyn B Ibberson; Corey P Parlet; Jakub Kwiecinski; Heidi A Crosby; David K Meyerholz; Alexander R Horswill
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

8.  Effects of Sodium Hyaluronate Eye Drops With or Without Preservatives on Ocular Surface Bacterial Microbiota.

Authors:  Yanlin Zhong; Xie Fang; Xuemei Wang; Yu-An Lin; Huping Wu; Cheng Li
Journal:  Front Med (Lausanne)       Date:  2022-02-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.